Roche Gets Hep C Inhibitor With Potential Twice Daily Dosing From InterMune
This article was originally published in The Pink Sheet Daily
Executive Summary
Investigational compound ITMN-191 is a candidate for use in combination with Pegasys, Roche says.
You may also be interested in...
Roche Advances In HCV Protease Inhibitor Contest
Swiss pharma will move ITMN-191 into Phase II studies, triggering a $15 million milestone to InterMune.
Roche Advances In HCV Protease Inhibitor Contest
Swiss pharma will move ITMN-191 into Phase II studies, triggering a $15 million milestone to InterMune.
Abbott Wins Rights To Enanta’s Preclinical HCV Protease Inhibitors
Collaboration moves Abbott into an increasingly competitive area of research.